161 related articles for article (PubMed ID: 10994152)
1. Effect of activated human protein C on experimental venous thrombosis induced by stasis with operative invasion in mice.
Aoki Y; Fukumoto Y; Inoue K; Katsuura Y; Komoriya K; Miyamoto S
Arzneimittelforschung; 2000 Aug; 50(8):695-9. PubMed ID: 10994152
[TBL] [Abstract][Full Text] [Related]
2. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats.
Aoki Y; Ota M; Katsuura Y; Komoriya K; Nakagaki T
Arzneimittelforschung; 2000 Sep; 50(9):809-15. PubMed ID: 11050697
[TBL] [Abstract][Full Text] [Related]
3. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
[TBL] [Abstract][Full Text] [Related]
4. Characteristic effects of activated human protein C on tissue thromboplastin-induced disseminated intravascular coagulation in rabbits.
Katsuura Y; Aoki K; Tanabe H; Kiyoki M; Funatsu A
Thromb Res; 1994 Nov; 76(4):353-62. PubMed ID: 7871494
[TBL] [Abstract][Full Text] [Related]
5. [Inhibitory effect of activated protein C and heparin on arterial thrombosis].
Araki H
Nihon Rinsho; 1992 Feb; 50(2):408-12. PubMed ID: 1613999
[TBL] [Abstract][Full Text] [Related]
6. The effect of taurolidine on experimental thrombus formation.
Kaptanoglu L; Kucuk HF; Colak E; Kurt N; Bingul SM; Akyol H; Torlak OA; Yazici F
Eur J Pharmacol; 2008 Jan; 578(2-3):238-41. PubMed ID: 17961549
[TBL] [Abstract][Full Text] [Related]
7. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects.
Okajima K; Koga S; Kaji M; Inoue M; Nakagaki T; Funatsu A; Okabe H; Takatsuki K; Aoki N
Thromb Haemost; 1990 Feb; 63(1):48-53. PubMed ID: 2140205
[TBL] [Abstract][Full Text] [Related]
8. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
Colucci M; Simioni P; Piro D; Prandoni P; Pagnan A; Semeraro N
Haematologica; 2003 Dec; 88(12):1383-9. PubMed ID: 14687992
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of microarterial thrombosis by activated protein C in a rabbit model.
Arnljots B; Bergqvist D; Dahlbäck B
Thromb Haemost; 1994 Sep; 72(3):415-20. PubMed ID: 7855793
[TBL] [Abstract][Full Text] [Related]
11. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
13. Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va.
Van Walderveen MC; Berry LR; Atkinson HM; Chan AK
Thromb Haemost; 2010 May; 103(5):910-9. PubMed ID: 20216984
[TBL] [Abstract][Full Text] [Related]
14. [Protein C, protein S and heparin cofactor II--their significance as the regulatory factors in the blood coagulation cascade].
Shinmyozu K
Rinsho Byori; 1994 Jan; 42(1):9-15. PubMed ID: 8107289
[TBL] [Abstract][Full Text] [Related]
15. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
Farias WR; Nazareth RA; Mourão PA
Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
[TBL] [Abstract][Full Text] [Related]
16. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
Xiong J; Fang W; Fang W; Bai L; Huo J; Kong Y; Yunman L
J Pharm Pharmacol; 2009 Jan; 61(1):89-94. PubMed ID: 19126301
[TBL] [Abstract][Full Text] [Related]
18. [Protein C: mechanisms of activation and anticoagulant effect].
Kogan AE; Strukova SM
Biokhimiia; 1993 Jun; 58(6):827-44. PubMed ID: 8364108
[TBL] [Abstract][Full Text] [Related]
19. The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va.
Nishioka J; Ido M; Hayashi T; Suzuki K
Thromb Haemost; 1996 Feb; 75(2):275-82. PubMed ID: 8815576
[TBL] [Abstract][Full Text] [Related]
20. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
